Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial.

Graillon T, Sanson M, Campello C, Idbaih A, Peyre M, Peyrière H, Basset N, Autran D, Roche C, Kalamarides M, Roche PH, Fuentes S, Tabouret E, Barrie M, Cohen A, Honoré S, Boucekine M, Baumstarck K, Figarella-Branger D, Barlier A, Dufour H, Chinot OL.

Clin Cancer Res. 2020 Feb 1;26(3):552-557. doi: 10.1158/1078-0432.CCR-19-2109. Epub 2020 Jan 22.

PMID:
31969329
2.

Management and outcome of primary CNS lymphoma in the modern era: An LOC network study.

Houillier C, Soussain C, Ghesquières H, Soubeyran P, Chinot O, Taillandier L, Lamy T, Choquet S, Ahle G, Damaj G, Agapé P, Moluçon-Chabrot C, Amiel A, Delwail V, Fabbro M, Jardin F, Chauchet A, Moles-Moreau MP, Morschhauser F, Casasnovas O, Gressin R, Fornecker LM, Abraham J, Marolleau JP, Tempescul A, Campello C, Colin P, Tamburini J, Laribi K, Serrier C, Haioun C, Chebrek S, Schmitt A, Blonski M, Houot R, Boyle E, Bay JO, Oberic L, Tabouret E, Waultier A, Martin-Duverneuil N, Touitou V, Cassoux N, Kas A, Mokhtari K, Charlotte F, Alentorn A, Feuvret L, Le Garff-Tavernier M, Costopoulos M, Mathon B, Peyre M, Delgadillo D, Douzane H, Genet D, Aidaoui B, Hoang-Xuan K, Gyan E.

Neurology. 2020 Jan 6. pii: 10.1212/WNL.0000000000008900. doi: 10.1212/WNL.0000000000008900. [Epub ahead of print]

PMID:
31907289
3.

CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.

Appay R, Dehais C, Maurage CA, Alentorn A, Carpentier C, Colin C, Ducray F, Escande F, Idbaih A, Kamoun A, Marie Y, Mokhtari K, Tabouret E, Trabelsi N, Uro-Coste E, Delattre JY, Figarella-Branger D; POLA Network.

Neuro Oncol. 2019 Dec 17;21(12):1519-1528. doi: 10.1093/neuonc/noz124.

PMID:
31832685
4.

High mitochondrial DNA copy number is associated with longer survival in young patients with glioblastoma.

Dardaud LM, Bris C, Desquiret-Dumas V, Boisselier B, Tabouret E, Mokhtari K, Figarella-Branger D, Rousseau A, Procaccio V.

Neuro Oncol. 2019 Apr 26. pii: noz072. doi: 10.1093/neuonc/noz072. [Epub ahead of print] No abstract available.

PMID:
31095694
5.

Correction to: Neuro-radiological characteristics of adult diffuse grade II and III insular gliomas classified according to WHO 2016.

Compes P, Tabouret E, Etcheverry A, Colin C, Appay R, Cordier N, Mosser J, Chinot O, Delingette H, Girard N, Dufour H, Metellus P, Figarella-Branger D.

J Neurooncol. 2019 May;142(3):521. doi: 10.1007/s11060-019-03141-y.

PMID:
30859482
6.

Neuro-radiological characteristics of adult diffuse grade II and III insular gliomas classified according to WHO 2016.

Compes P, Tabouret E, Etcheverry A, Colin C, Appay R, Cordier N, Mosser J, Chinot O, Delingette H, Girard N, Dufour H, Metellus P, Figarella-Branger D.

J Neurooncol. 2019 May;142(3):511-520. doi: 10.1007/s11060-019-03122-1. Epub 2019 Feb 11. Erratum in: J Neurooncol. 2019 Mar 11;:.

PMID:
30756272
7.

Leptomeningeal Gliomatosis: A Single Institution Study of 31 Patients.

Autran D, Barrie M, Matta M, Monserrat C, Campello C, Petrirena G, Boucard C, Padovani L, Loundou A, Appay R, Graillon T, Dufour H, Figarella-Branger D, Chinot O, Tabouret E.

Anticancer Res. 2019 Feb;39(2):1035-1041. doi: 10.21873/anticanres.13210.

PMID:
30711992
8.

(R)-GEMOX chemotherapy for unfit patients with refractory or recurrent primary central nervous system lymphoma: a LOC study.

Collignon A, Houillier C, Ahle G, Chinot O, Choquet S, Schmitt A, Agape P, Soussain C, Hoang-Xuan K, Tabouret E.

Ann Hematol. 2019 Apr;98(4):915-922. doi: 10.1007/s00277-018-3564-6. Epub 2018 Dec 7.

PMID:
30535802
9.

Negative Survival Impact of High Radiation Doses to Neural Stem Cells Niches in an IDH-Wild-Type Glioblastoma Population.

Muracciole X, El-Amine W, Tabouret E, Boucekine M, Barlier A, Petrirena G, Harivony T, Solignac L, Chinot OL, Macagno N, Figarella-Branger D, Padovani L.

Front Oncol. 2018 Oct 4;8:426. doi: 10.3389/fonc.2018.00426. eCollection 2018.

10.

Somatostatin receptor 2A protein expression characterizes anaplastic oligodendrogliomas with favorable outcome.

Appay R, Tabouret E, Touat M, Carpentier C, Colin C, Ducray F, Idbaih A, Mokhtari K, Uro-Coste E, Dehais C, Figarella-Branger D; POLA network.

Acta Neuropathol Commun. 2018 Sep 7;6(1):89. doi: 10.1186/s40478-018-0594-1.

11.

Coping strategies and quality of life: a longitudinal study of high-grade glioma patient-caregiver dyads.

Baumstarck K, Chinot O, Tabouret E, Farina P, Barrié M, Campello C, Petrirena G, Hamidou Z, Auquier P.

Health Qual Life Outcomes. 2018 Aug 2;16(1):157. doi: 10.1186/s12955-018-0983-y.

12.

IDH2 mutations are commonly associated with 1p/19q codeletion in diffuse adult gliomas.

Appay R, Tabouret E, Macagno N, Touat M, Carpentier C, Colin C, Ducray F, Idbaih A, Mokhtari K, Uro-Coste E, Dehais C, Figarella-Branger D; POLA Network.

Neuro Oncol. 2018 Apr 9;20(5):716-718. doi: 10.1093/neuonc/noy014. No abstract available.

13.

Recurrent extraneural sonic hedgehog medulloblastoma exhibiting sustained response to vismodegib and temozolomide monotherapies and inter-metastatic molecular heterogeneity at progression.

Petrirena GJ, Masliah-Planchon J, Sala Q, Pourroy B, Frappaz D, Tabouret E, Graillon T, Gentet JC, Delattre O, Chinot O, Padovani L.

Oncotarget. 2018 Jan 3;9(11):10175-10183. doi: 10.18632/oncotarget.23699. eCollection 2018 Feb 9.

14.

Differential scanning calorimetry of plasma in glioblastoma: toward a new prognostic / monitoring tool.

Tsvetkov PO, Tabouret E, Roman AY, Romain S, Bequet C, Ishimbaeva O, Honoré S, Figarella-Branger D, Chinot O, Devred F.

Oncotarget. 2018 Jan 25;9(10):9391-9399. doi: 10.18632/oncotarget.24317. eCollection 2018 Feb 6.

15.

Rational use of systematic postoperative CT scans after neurosurgical craniotomy.

Boissonneau S, Tabouret E, Graillon T, Meyer M, Velly LJ, Girard N, Brunel H, Bruder NJ, Fuentes S, Dufour H.

J Neurosurg Sci. 2017 Sep 28. doi: 10.23736/S0390-5616.17.04082-6. [Epub ahead of print]

PMID:
28959872
16.

Relationship between magnetic resonance imaging characteristics and plasmatic levels of MMP2 and MMP9 in patients with recurrent high-grade gliomas treated by Bevacizumab and Irinotecan.

Farina P, Tabouret E, Lehmann P, Barrie M, Petrirena G, Campello C, Boucard C, Graillon T, Girard N, Chinot O.

J Neurooncol. 2017 May;132(3):433-437. doi: 10.1007/s11060-017-2385-0. Epub 2017 Mar 6.

PMID:
28265824
17.

Patterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: imaging analysis of the ANOCEF-GOELAMS prospective randomized trial.

Tabouret E, Houillier C, Martin-Duverneuil N, Blonski M, Soussain C, Ghesquières H, Houot R, Larrieu D, Soubeyran P, Gressin R, Gyan E, Chinot O, Taillandier L, Choquet S, Alentorn A, Leclercq D, Omuro A, Tanguy ML, Hoang-Xuan K.

Neuro Oncol. 2017 Mar 1;19(3):422-429. doi: 10.1093/neuonc/now238.

18.

Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort.

Tabouret E, Nguyen AT, Dehais C, Carpentier C, Ducray F, Idbaih A, Mokhtari K, Jouvet A, Uro-Coste E, Colin C, Chinot O, Loiseau H, Moyal E, Maurage CA, Polivka M, Lechapt-Zalcman E, Desenclos C, Meyronet D, Delattre JY, Figarella-Branger D; For POLA Network.

Acta Neuropathol. 2016 Oct;132(4):625-34. doi: 10.1007/s00401-016-1611-8. Epub 2016 Aug 29.

PMID:
27573687
19.

Changes in PlGF and MET-HGF expressions in paired initial and recurrent glioblastoma.

Tabouret E, Denicolai E, Delfino C, Graillon T, Boucard C, Nanni I, Padovani L, Figarella-Branger D, Chinot O.

J Neurooncol. 2016 Dec;130(3):431-437. Epub 2016 Aug 26.

PMID:
27566180
20.

Inhibitor of apoptosis protein expression in glioblastomas and their in vitro and in vivo targeting by SMAC mimetic GDC-0152.

Tchoghandjian A, Soubéran A, Tabouret E, Colin C, Denicolaï E, Jiguet-Jiglaire C, El-Battari A, Villard C, Baeza-Kallee N, Figarella-Branger D.

Cell Death Dis. 2016 Aug 4;7(8):e2325. doi: 10.1038/cddis.2016.214.

21.

Coping with a newly diagnosed high-grade glioma: patient-caregiver dyad effects on quality of life.

Baumstarck K, Leroy T, Hamidou Z, Tabouret E, Farina P, Barrié M, Campello C, Petrirena G, Chinot O, Auquier P.

J Neurooncol. 2016 Aug;129(1):155-64. doi: 10.1007/s11060-016-2161-6. Epub 2016 Jun 14.

PMID:
27300523
22.

[ESMO ECCO 2015: The highlights of immunotherapy and targeted therapies].

Bonnet C, Beinse G, Cabel L, Cochereau D, Lavaud P, Rochefort P, Tabouret E, Turpin A, Verlingue L, Vicier C, Massard C.

Bull Cancer. 2016 Jun;103(6):594-603. doi: 10.1016/j.bulcan.2016.04.001. Epub 2016 May 24. French.

PMID:
27229364
23.

Supratentorial clear cell ependymomas with branching capillaries demonstrate characteristic clinicopathological features and pathological activation of nuclear factor-kappaB signaling.

Figarella-Branger D, Lechapt-Zalcman E, Tabouret E, Jünger S, de Paula AM, Bouvier C, Colin C, Jouvet A, Forest F, Andreiuolo F, Quintin-Roue I, Machet MC, Heitzmann A, Milin S, Sevestre H, Godfraind C, Labrousse F, Metellus P, Scavarda D, Pietsch T.

Neuro Oncol. 2016 Jul;18(7):919-27. doi: 10.1093/neuonc/now025. Epub 2016 Mar 15.

24.

[An atypical form of ocular involvement in cat scratch disease].

Barreau G, Buil O, Tabouret E, Robert PY.

J Fr Ophtalmol. 2016 Mar;39(3):e59-61. doi: 10.1016/j.jfo.2014.09.034. Epub 2016 Mar 3. French. No abstract available.

PMID:
26947323
25.

MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study.

Tabouret E, Bertucci F, Pierga JY, Petit T, Levy C, Ferrero JM, Campone M, Gligorov J, Lerebours F, Roché H, Bachelot T, van Laere S, Ueno NT, Toiron Y, Finetti P, Birnbaum D, Borg JP, Viens P, Chinot O, Gonçalves A.

Oncotarget. 2016 Apr 5;7(14):18531-40. doi: 10.18632/oncotarget.7612.

26.

Complications Related to the Endoscopic Endonasal Transsphenoidal Approach for Nonfunctioning Pituitary Macroadenomas in 300 Consecutive Patients.

Magro E, Graillon T, Lassave J, Castinetti F, Boissonneau S, Tabouret E, Fuentes S, Velly L, Gras R, Dufour H.

World Neurosurg. 2016 May;89:442-53. doi: 10.1016/j.wneu.2016.02.059. Epub 2016 Feb 20.

PMID:
26902781
27.

Molecular heterogeneity of glioblastomas: does location matter?

Denicolaï E, Tabouret E, Colin C, Metellus P, Nanni I, Boucard C, Tchoghandjian A, Meyronet D, Baeza-Kallee N, Chinot O, Figarella-Branger D.

Oncotarget. 2016 Jan 5;7(1):902-13. doi: 10.18632/oncotarget.6433.

28.

Neuro-oncological patients admitted in intensive-care unit: predictive factors and functional outcome.

Tabouret E, Boucard C, Devillier R, Barrie M, Boussen S, Autran D, Chinot O, Bruder N.

J Neurooncol. 2016 Mar;127(1):111-7. doi: 10.1007/s11060-015-2015-7. Epub 2015 Nov 25.

PMID:
26608523
29.

BRAF mutation and anaplasia may be predictive factors of progression-free survival in adult pleomorphic xanthoastrocytoma.

Tabouret E, Bequet C, Denicolaï E, Barrié M, Nanni I, Metellus P, Dufour H, Chinot O, Figarella-Branger D.

Eur J Surg Oncol. 2015 Dec;41(12):1685-90. doi: 10.1016/j.ejso.2015.09.012. Epub 2015 Sep 30.

PMID:
26454767
30.

LRP1B deletion is associated with poor outcome for glioblastoma patients.

Tabouret E, Labussière M, Alentorn A, Schmitt Y, Marie Y, Sanson M.

J Neurol Sci. 2015 Nov 15;358(1-2):440-3. doi: 10.1016/j.jns.2015.09.345. Epub 2015 Sep 11.

PMID:
26428308
31.

TERT promoter mutations in primary central nervous system lymphoma are associated with spatial distribution in the splenium.

Bruno A, Alentorn A, Daniau M, Labussière M, Rahimian A, Tabouret E, Polivka M, Jouvet A, Adam C, Figarella-Branger D, Chrétien F, Eimer S, Houillier C, Soussain C, Mokhtari K, Hoang-Xuan K.

Acta Neuropathol. 2015 Sep;130(3):439-40. doi: 10.1007/s00401-015-1461-9. Epub 2015 Jul 21. No abstract available.

PMID:
26195323
32.

MMP2 and MMP9 as candidate biomarkers to monitor bevacizumab therapy in high-grade glioma.

Tabouret E, Boudouresque F, Farina P, Barrié M, Bequet C, Sanson M, Chinot O.

Neuro Oncol. 2015 Aug;17(8):1174-6. doi: 10.1093/neuonc/nov094. No abstract available.

33.

Relationships Between Dose Intensity, Toxicity, and Outcome in Patients with Oligodendroglial Tumors Treated with the PCV Regimen.

Tabouret E, Reyes-Botero G, Dehais C, Daros M, Barrie M, Matta M, Petrirena G, Autran D, Duran A, Bequet C, Delattre JY, Chinot O.

Anticancer Res. 2015 May;35(5):2901-8.

PMID:
25964574
34.

Which one is a valuable surrogate for predicting survival between Tomita and Tokuhashi scores in patients with spinal metastases? A meta-analysis for diagnostic test accuracy and individual participant data analysis.

Lee CH, Chung CK, Jahng TA, Kim KJ, Kim CH, Hyun SJ, Kim HJ, Jeon SR, Chang UK, Lee SH, Moon SH, Majeed H, Zhang D, Gravis G, Wibmer C, Kumar N, Moon KY, Park JH, Tabouret E, Fuentes S.

J Neurooncol. 2015 Jun;123(2):267-75. doi: 10.1007/s11060-015-1794-1. Epub 2015 May 7.

PMID:
25947287
35.

Recurrence of glioblastoma after radio-chemotherapy is associated with an angiogenic switch to the CXCL12-CXCR4 pathway.

Tabouret E, Tchoghandjian A, Denicolai E, Delfino C, Metellus P, Graillon T, Boucard C, Nanni I, Padovani L, Ouafik L, Figarella-Branger D, Chinot O.

Oncotarget. 2015 May 10;6(13):11664-75.

36.

End-binding 1 protein overexpression correlates with glioblastoma progression and sensitizes to Vinca-alkaloids in vitro and in vivo.

Berges R, Baeza-Kallee N, Tabouret E, Chinot O, Petit M, Kruczynski A, Figarella-Branger D, Honore S, Braguer D.

Oncotarget. 2014 Dec 30;5(24):12769-87.

37.

Long-term survivors after surgical management of metastatic spinal cord compression.

Tabouret E, Gravis G, Cauvin C, Loundou A, Adetchessi T, Fuentes S.

Eur Spine J. 2015 Jan;24(1):209-15. doi: 10.1007/s00586-014-3676-1. Epub 2014 Nov 19.

PMID:
25408254
38.

Gliomas.

Lombardi G, Della Puppa A, Di Stefano AL, Pace A, Rudà R, Tabouret E, Zagonel V.

Biomed Res Int. 2014;2014:470523. doi: 10.1155/2014/470523. Epub 2014 Aug 26. No abstract available.

39.

Predictive biomarkers investigated in glioblastoma.

Tabouret E, Chinot O, Sanson M, Loundou A, Hoang-Xuan K, Delattre JY, Idbaih A.

Expert Rev Mol Diagn. 2014 Sep;14(7):883-93. doi: 10.1586/14737159.2014.945436. Epub 2014 Aug 5. Review.

PMID:
25096963
40.

Systemic treatments for brain metastases from breast cancer, non-small cell lung cancer, melanoma and renal cell carcinoma: an overview of the literature.

Lombardi G, Di Stefano AL, Farina P, Zagonel V, Tabouret E.

Cancer Treat Rev. 2014 Sep;40(8):951-9. doi: 10.1016/j.ctrv.2014.05.007. Epub 2014 May 27. Review.

PMID:
24909312
41.

New IDH1 I113T mutation associated with BRAF V600E mutation: new driver of gliomagenesis?

Tabouret E, Fina F, Vincentelli F, Nanni I, Figarella-Branger D.

J Neurol Sci. 2014 Jul 15;342(1-2):204-6. doi: 10.1016/j.jns.2014.05.010. Epub 2014 May 15.

PMID:
24857351
42.

Primary neurolymphomatosis diagnosis and treatment: a retrospective study.

Lagarde S, Tabouret E, Matta M, Franques J, Attarian S, Pouget J, Maues De Paula A, Figarella-Branger D, Dory-Lautrec P, Chinot O, Barrié M.

J Neurol Sci. 2014 Jul 15;342(1-2):178-81. doi: 10.1016/j.jns.2014.04.030. Epub 2014 May 1.

PMID:
24831985
43.

Bing-Neel syndrome: a cerebral Richter syndrome?

Tabouret E, Coso D, Matta M, Barrié M, Bouabdallah R, Chinot O.

Neurol India. 2014 Mar-Apr;62(2):229-30. doi: 10.4103/0028-3886.132451. No abstract available.

44.

[HPV prophylactic vaccine coverage and factors impacting its practice among students and high school students in Marseilles' area].

Baudoin A, Sabiani L, Oundjian F, Tabouret E, Agostini A, Courbière B, Boubli L, Carcopino X.

J Gynecol Obstet Biol Reprod (Paris). 2015 Feb;44(2):126-35. doi: 10.1016/j.jgyn.2014.02.005. Epub 2014 Apr 2. French.

45.

High-grade glioma in elderly patients: can the oncogeriatrician help?

Tabouret E, Tassy L, Chinot O, Crétel E, Retornaz F, Rousseau F.

Clin Interv Aging. 2013;8:1617-24. doi: 10.2147/CIA.S35941. Epub 2013 Dec 6. Review.

46.

Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma.

Tabouret E, Boudouresque F, Barrie M, Matta M, Boucard C, Loundou A, Carpentier A, Sanson M, Metellus P, Figarella-Branger D, Ouafik L, Chinot O.

Neuro Oncol. 2014 Mar;16(3):392-9. doi: 10.1093/neuonc/not226. Epub 2013 Dec 9.

47.

Assessment of prognostic scores in brain metastases from breast cancer.

Tabouret E, Metellus P, Gonçalves A, Esterni B, Charaffe-Jauffret E, Viens P, Tallet A.

Neuro Oncol. 2014 Mar;16(3):421-8. doi: 10.1093/neuonc/not200. Epub 2013 Dec 4.

48.

Reassessment of scoring systems and prognostic factors for metastatic spinal cord compression.

Tabouret E, Cauvin C, Fuentes S, Esterni B, Adetchessi T, Salem N, Madroszyk A, Gonçalves A, Casalonga F, Gravis G.

Spine J. 2015 May 1;15(5):944-50. doi: 10.1016/j.spinee.2013.06.036. Epub 2013 Oct 9.

PMID:
24120144
49.

BetaHCG secretion by a pulmonary adenocarcinoma.

Vicier C, Tabouret E, Tallet A, Gonçalves A, Chetaille B, Viens P, Madroszyk A.

World J Surg Oncol. 2013 Sep 14;11:228. doi: 10.1186/1477-7819-11-228.

50.

Limited impact of prognostic factors in patients with recurrent glioblastoma multiforme treated with a bevacizumab-based regimen.

Tabouret E, Barrie M, Thiebaut A, Matta M, Boucard C, Autran D, Loundou A, Chinot O.

J Neurooncol. 2013 Sep;114(2):191-8. doi: 10.1007/s11060-013-1170-y. Epub 2013 Jun 12.

PMID:
23756726

Supplemental Content

Loading ...
Support Center